NCT04820608 is a NA clinical trial of Cross-linking in Keratoconus, sponsored by Ophthalmica Eye Institute.

Who is sponsoring NCT04820608?

NCT04820608 is sponsored by Ophthalmica Eye Institute.

What drugs are being tested in NCT04820608?

Interventions in NCT04820608: Cross-linking.

What condition does NCT04820608 study?

NCT04820608 studies Keratoconus.

Is NCT04820608 still recruiting?

NCT04820608 is currently status unknown. Last updated 29 March 2021.

Last reviewed 2021-03-29 · How we verify

NCT04820608

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transepithelial Customized Cross-linking

Status unknown NA Last updated 29 March 2021

What this trial tests

NA trial testing Cross-linking in Keratoconus in 50 participants. Status unknown.

Timeline

1 February 2018

Primary endpoint
1 January 2022

1 January 2022

Quick facts

Lead sponsor	Ophthalmica Eye Institute
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 February 2018
Primary completion	1 January 2022
Estimated completion	1 January 2022
Sites	1 location across Greece

Drugs / interventions tested

Cross-linking

Conditions studied

Keratoconus — all drugs for Keratoconus →

Sponsor

Ophthalmica Eye Institute

Who can join

Adults 12 to 55, any sex, with Keratoconus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Customized remodeled vision (CuRV) is a new corneal cross-linking protocol for keratoconus, combining a transepithelial approach with customized energy application. Our aim is to follow-up our patients and establish the short-and long-term results of CuRV.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Keratoconus

Currently open trials in the same condition.

NCT07372911 — PRoTECT: Corneal Wavefront Guided PRK + Epi-off CXL vs. PTK+Epi-off CXL in Keratoconus · NA · recruiting
NCT07461129 — Electrophysiological Changes in Cases of Different Stages of Keratoconus · active not recruiting
NCT06601101 — Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus · Phase 3 · recruiting
NCT05516004 — Safety and Effectiveness of the PXL-Platinum 330 System for Cornea Crosslinking in Eyes With Cornea Thinning · Phase 2 · recruiting
NCT06798779 — Predicting Manifest Astigmatism in Keratoconus Patients. · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04820608 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ophthalmica Eye Institute
Last refreshed: 29 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04820608.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing